Concordance of folate receptor-α expression between biopsy, primary tumor and metastasis in breast cancer and lung cancer patients.
Concordance of folate receptor-α expression between biopsy, primary tumor and metastasis in breast cancer and lung cancer patients.
复制标题
DOI：
10.18632/oncotarget.7856
复制
发表时间：
2016-04-05
期刊：
影响因子：
--
通讯作者：
Vahrmeijer AL
中科院分区：
文献类型：
--
作者：
Boogerd LS;Boonstra MC;Beck AJ;Charehbili A;Hoogstins CE;Prevoo HA;Singhal S;Low PS;van de Velde CJ;Vahrmeijer AL
已知叶酸受体α(FRα)在多种癌症中表达上调，包括非小细胞肺癌和乳腺癌。为了确保可靠的诊断和治疗药物的实施，活检、原发肿瘤和转移瘤之间FRα表达的一致性是重要的。应用免疫组织化学方法(Mc26B3.F2)对60例非小细胞肺癌和40例乳腺癌患者进行了检测。乳腺癌和肺癌活检组织中FRα表达的假阳性率限制在5%以下。在非小细胞肺癌中，21/34例腺癌和4/26例鳞癌中均有FRα表达。腺癌和鳞癌组织中FRα表达与原发灶的符合率分别为83%和91%。在所有局部和远处转移的非小细胞肺癌患者中，大约80%的FRα表达与其对应的原发肿瘤一致。乳腺癌组织中FRα阳性12/40，肿块切除20/40，淋巴结转移6/20，活检与原发灶符合率为68%，原发灶与转移灶符合率为60%。总之，这项研究表明，与原发非小细胞肺癌和乳腺癌相比，活检和转移组织中FRα表达的符合率很高，强调了FRα靶向药物在这些患者中的适用性。
Folate receptor alpha (FRα) is known to be upregulated in a variety of cancers, including non-small cell lung cancer (NSCLC) and breast cancer. To ensure reliable implementation of diagnostic- and therapeutic agents, concordance of FRα expression between biopsy, primary tumor and metastases is important. Using immunohistochemistry (Mab 26B3.F2) these concordances were investigated in 60 NSCLC and 40 breast cancer patients. False positivity of FRα expression on breast and lung cancer biopsies was limited to less than 5%. In NSCLC, FRα expression was shown in 21/34 adenocarcinomas and 4/26 squamous cell carcinomas (SCC). Concordance of FRα expression between biopsy and primary tumor was achieved in respectively 83% and 91% of adenocarcinomas and SCCs. Approximately 80% of all local and distant metastases of NSCLC patients showed concordant FRα expression as their corresponding primary tumor. In breast cancer, FRα positivity was shown in 12/40 biopsies, 20/40 lumpectomies and 6/20 LN metastases, with concordance of 68% between biopsy and primary tumor and 60% between primary tumor and LN metastases. In conclusion, this study shows high concordance rates of FRα expression between biopsies and metastases compared to primary NSCLC and breast cancers, underscoring the applicability of FRα-targeted agents in these patients.